Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: A prospective study

Gastroenterology

Volumn 97, Issue 4, 1989, Pages 827-836

  Maton, P N ^a   Vinayek, R ^a   Frucht, H ^a   McArthur, K A ^a   Miller, L S ^a   Saeed, Z A ^a   Gardner, J D ^a   Jensen, R T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; HISTAMINE H2 RECEPTOR; OMEPRAZOLE;

ACID SECRETION; ADULT; AGED; CLINICAL ARTICLE; FEMALE; GASTRINOMA; HUMAN; MALE; PEPTIC ULCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH PH; ZOLLINGER ELLISON SYNDROME;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRIC ACID; GASTRIC MUCOSA; HUMAN; INTESTINAL MUCOSA; MALE; MIDDLE AGE; OMEPRAZOLE; PROSPECTIVE STUDIES; TIME FACTORS; ZOLLINGER-ELLISON SYNDROME;

EID: 0024428379     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/0016-5085(89)91485-6     Document Type: Article

References (54)

1. Inhibition of gastric acid secretion by omeprazole in the dog and rat
2. Effects of substituted benzimidazole (H 149/94) on gastric acid secretion in humans
3. +-ATPase
4. +) ATPase
5. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome
6. 2-receptor antagonists
7. Omeprazole in the medical treatment of Zollinger-Ellison syndrome
8. Omeprazole in the Zollinger-Ellison syndrome
9. 2-receptor antagonists
10. 2-histamine receptor blocking agents in the Zollinger-Ellison syndrome
11. Medical and surgical options in the management of patients with gastrinoma
12. Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion
13. 2-receptor antagonists: a prospective study
14. Use of ranitidine in the medical treatment of Zollinger-Ellison syndrome
15. Famotidine in the therapy of gastric hypersecretory states
16. Effect of isopropamide on response to oral cimetidine in patients with Zollinger-Ellison syndrome
17. Effect of omeprazole on gastric acid secretion in human volunteers
18. Omeprazole inhibits oxidative drug metabolism
19. Omeprazole: effects on oxidative drug metabolism
20. Toxicological studies on omeprazole
21. Enterochromaffin-like cell carcinoids of gastric mcosa in rats after life-long inhibition of gastric secretion
22. Plasma gastrin and gastric enterochromaffin cell activation and proliferation—studies with omeprazole and ranitidine in intact and antrectomized rats
23. Assessing the safety of drugs for the long-term treatment of peptic ulcers
24. Acid secretion during and after omeprazole treatment in healthy volunteers
25. Acid secretory capacity after treatment with omeprazole
26. The effect of oral omeprazole on serum gastrin and serum pepsinogen I levels
27. Zollinger-Ellison syndrome: current concepts in management
28. Use of calcium and secretin in the diagnosis of gastrinoma (Zollinger-Ellison syndrome)
29. Prospective study of the ability of computed axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome
30. Role of selective angiography in the management of patients with Zollinger-Ellison syndrome
31. Prospective study of chemotherapy in patients with metastatic gastrinoma
32. Long-term medical therapy in Zollinger-Ellison syndrome (ZES) (abstr)
33. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome
34. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study
35. 2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome (ZES)
36. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study
37. Comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers
38. Kurzzeit Therapie des Ulcus duodeni mit Omeprazol und Ranitidin
39. Effect of omeprazole and cimetidine on duodenal ulcer
40. Omeprazole and ranitidine in the treatment of reflux-esophagitis: double blind comparative trial
41. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis
42. Differences in healing tendency of reflux esophagitis with omeprazole and ranitidine Results of an Austrian-German-Swiss multicenter trial
43. Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome
44. Cimetidine pharmacokinetics in patients with Zollinger-Ellison syndrome
45. Effect of omeprazole—a gastric proton pump inhibitor—on pentagastrin stimulated acid secretion in man
46. A multicenter U.S. study of omeprazole treatment of Zollinger-Ellison syndrome (abstr)
47. Esophageal involvement in Zollinger-Ellison syndrome (ZES) (abstr)
48. Cimetidine and ranitidine in duodenal ulcer
49. Ranitidine in longterm duodenal ulcer treatment: a multicenter trial
50. 2-receptor antagonists (abstr)
51. Gastric carcinoids and related endocrine growths
52. Development of gastric argyrophil carcinoid tumor in a case of Zollinger-Ellison syndrome with primary hyperparathyroidism during long-term antisecretory treatment
53. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia
54. Argyrophil cell hyperplasia of fundic mucosa in patients with chronic atrophic gastritis